Grave’s Ophthalmopathy (GO), also known as
thyroid eye disease (TED), is an autoimmune
disorder that affects your eyes. The body’s
immune system mistakenly attacks the muscles
and other tissues around the eyes, causing
unpleasant and often painful symptoms.
About 1 in 20 people who are living with Graves’ disease also experience GO. Eye symptoms most often begin within 6 months of a Graves’ disease diagnosis.
The most common symptoms of moderate-to-severe GO are swelling and redness of the eyelids, eye irritation and a dry, gritty feeling eyelid retraction – your eyelid is sitting high on top of the eye, causing more of your eye to show than usual, double vision (also known as diplopia), bulging of the eyes (also known as proptosis)
Immunovant’s investigational product candidate, RVT-1401 (also known as IMVT-1401), is a novel, fully human monoclonal antibody that targets the immune system. It is hoped that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection.